With the recent surge in partnerships, collaborations, and M&A, this discussion will cover how these developments will likely shape the future of the sector . Participants will also explore the key elements for successful partnerships over the next 3-5 years as well as what commercial scalability for cell and gene therapies will look like .

Chair:
Morrie Ruffin, Co-Founder and Senior Advisor, Alliance for Regenerative Medicine (ARM)

Speakers:
Amy DuRoss, Co-Founder and CEO, Vineti
Sven Kili, M.D., Principal, Sven Kili Consulting
John Tchelingerian, Ph.D., President and CEO, Promethera Biosciences
Christopher Vann, Chief Operating Officer, Autolus Therapeutics
Rogerio Vivaldi, M.D., President and CEO, Sigilon Therapeutics

свернуть